RespireRx Pharmaceuticals Inc (fka RSPI)

[davidal66]

Again, the test augers well for ADHD. Very well for RD and especially for ADHD. I believe this effect of insomnia as reported in the CX717 study/and contracted, less sleep, in the apnea study strongly suggests a class effect in ADHD and disorders related therein. Keep in mind, the ampakine here was administered late in the day, but in the ADHD trial the ampakine would be given early in the day. This doesn't change the management status or cash on hand status or stock price status(immediately), but is indicative of a bullseye in ADHD and RD in my book.